Is Fezonatant covered by medical insurance? Can patients be reimbursed for the cost of this drug through medical insurance?

Fezolinetant (Fezolinetant) is not currently on the market in China, so it has not yet been included in my country's medical insurance directory. Since the medical insurance policy only applies to drugs that have been approved and marketed in China, patients are temporarily unable to be reimbursed through medical insurance. This means that patients who want to use the drug need to bear the entire cost of purchasing the drug themselves, or obtain treatment through other means.

Since Fezolnetam has not yet been sold in China, domestic patients can only purchase drugs through overseas channels if they need medicine. At present, the overseas version of fezonatant mainly includes the generic version of Lucius from Laos, with a specification of 45mg*30 tablets and a price of around 900 yuan. Compared with the prices of original drugs in some European and American markets, the Laos version is more affordable. However, when patients choose to purchase drugs overseas, they still need to ensure that the drugs come from regular sources to ensure quality and safety.

From the perspective of the possibility of inclusion in medical insurance, if filazonatant is approved for marketing in China in the future, whether it can be included in the medical insurance catalog will still depend on national medical insurance negotiations and the clinical demand and cost-effectiveness assessment of the drug. If pharmaceutical companies are willing to lower their prices and undergo review by the Medical Insurance Bureau, they may be included in medical insurance through negotiations in the future, but the specific situation will be subject to national policy adjustments.

At present, there is no official information indicating that Fezonatant will be launched in China in the near future. Therefore, if patients need to purchase drugs, they need to understand the process of purchasing drugs overseas in advance and use the drug rationally under the guidance of professional doctors. In addition, as the international market pays more attention to menopausal treatment drugs, more alternative treatment options may appear in China in the future, providing patients with more choices.

Reference materials:https://www.veozah.com/